When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – TNFerade biologic, a novel method of delivering tumor necrosis factor to tumor cells by gene transfer, does not prolong survival when added to…
NEW YORK (Reuters Health) – Patients with non-castrate metastatic prostate cancer receiving androgen deprivation therapy fare no better with the addition of docetaxel chemotherapy, a French and Belgian…
Hanne Mintz, co-chair of the Meso Foundation Board of Directors, discusses the foundation’s goals to find effective treatment and ultimately a cure for mesothelioma. She recommends both physicians…
NEW YORK (Reuters Health) – Aggressive CT or PET/CT surveillance protocols confer significant risk of radiation-induced cancer in patients being monitored for metastasis from primary choroidal melanoma, California-based…
Robert Komitor, an attorney at Levy Philips & Konigsberg, LLP, discusses the best way for mesothelioma patients to receive compensation. Asbestos exposure is the only known and well…
NEW YORK (Reuters Health) – In HIV patients with anal intraepithelial neoplasia (AIN), infrared coagulation (IRC) helps avoid progression to squamous cell carcinoma (SCC), Spanish doctors say. “High-grade…
NEW YORK (Reuters Health) – Men with isolated high-grade prostatic intraepithelial neoplasia (HGPIN) are at relatively high risk for developing prostate cancer, and treatment with toremifene does not…
NEW YORK (Reuters Health) – Among patients undergoing liver transplantation for hepatocellular carcinoma, the risk of recurrence is lower when immunosuppression is based on sirolimus rather than calcineurin…
NEW YORK (Reuters Health) – A French team reports some advantages with robot-assisted compared to conventional laparoscopic radical prostatectomy performed via an extraperitoneal approach. “This study did not…
Lee Krug, MD, discusses the current state of mesothelioma treatments as well as new therapies in development. He mentions the possibilities of clinical trials for angiogenesis inhibitors and anti-VEGF antibodies for mesothelioma…
